Evidence map›Paper›PMID 25979787›Full record

ArticleBehavioural brain research2015

Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.

Mei Qin, Zachary Zeidler, Kristen Moulton, Leland Krych, Zengyan Xia, Carolyn B Smith

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Behavioural brain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Endocannabinoid contributions to the perception of socially relevant, affective touch in humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  11. Review
  12. Lipid-Based Molecules on Signaling Pathways in Autism Spectrum Disorder.International journal of molecular sciences · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  17. Article
  18. Genes · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mei QinSection on Neuroadaptation and Protein Metabolism, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bldg. 10, Rm. 2D54, Bethesda, MD 20892, USA.
Zachary ZeidlerSection on Neuroadaptation and Protein Metabolism, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bldg. 10, Rm. 2D54, Bethesda, MD 20892, USA.
Kristen MoultonSection on Neuroadaptation and Protein Metabolism, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bldg. 10, Rm. 2D54, Bethesda, MD 20892, USA.
Leland KrychSection on Neuroadaptation and Protein Metabolism, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bldg. 10, Rm. 2D54, Bethesda, MD 20892, USA.
Zengyan XiaSection on Neuroadaptation and Protein Metabolism, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bldg. 10, Rm. 2D54, Bethesda, MD 20892, USA.
Carolyn B SmithSection on Neuroadaptation and Protein Metabolism, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bldg. 10, Rm. 2D54, Bethesda, MD 20892, USA. Electronic address: beebe@mail.nih.gov.
National Institutes of Health · US

Funding

Studies On Protein Synthesis And Long-Term Adaptive Responses in the CNSZIAMH000889 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI BEEBE SMITH, CAROLYN · 2009 to 2021
$18.6M
Intramural NIH HHS ZIA MH000889
6 · The paper itself

Abstract

Silencing the gene FMR1 in fragile X syndrome (FXS) with consequent loss of its protein product, FMRP, results in intellectual disability, hyperactivity, anxiety, seizure disorders, and autism-like behavior. In a mouse model (Fmr1 knockout (KO)) of FXS, a deficit in performance on the passive avoidance test of learning and memory is a robust phenotype. We report that drugs acting on the endocannabinoid (eCB) system can improve performance on this test. We present three lines of evidence: (1) Propofol (reported to inhibit fatty acid amide hydrolase (FAAH) activity) administered 30 min after training on the passive avoidance test improved performance in Fmr1 KO mice but had no effect on wild type (WT). FAAH catalyzes the metabolism of the eCB, anandamide, so its inhibition should result in increased anandamide levels. (2) The effect of propofol was blocked by prior administration of the cannabinoid receptor 1 antagonist AM-251. (3) Treatment with the FAAH inhibitor, URB-597, administered 30 min after training on the passive avoidance test also improved performance in Fmr1 KO mice but had no effect on WT. Our results indicate that the eCB system is involved in FXS and suggest that the eCB system is a promising target for treatment of FXS.

Indexed as

AmidohydrolasesAnimalsAnxietyArachidonic AcidsAvoidance LearningBenzamidesCannabinoid Receptor AntagonistsCarbamatesDisease Models, AnimalEndocannabinoidsEnzyme InhibitorsFatty Acid Amide HydrolasesFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeMaleMemoryAM 251AmidohydrolasesanandamideArachidonic AcidsBenzamidesCannabinoid Receptor AntagonistsCarbamatesCNR1 protein, mousecyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl esterEndocannabinoidsEnzyme InhibitorsFatty Acid Amide HydrolasesFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1PiperidinesPolyunsaturated AlkamidesPropofolPyrazolesReceptor, Cannabinoid, CB1Receptors, GABA-AFAAHFmr1 KO miceFragile X syndromeMemoryPassive avoidancePropofol

Identifiers

PMID25979787
PMCPMC5003021
OpenAlexW1674182966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.